NFKB1 and colorectal carcinoma: Erythromycin, a macrolide antibiotic, inhibited the transcriptional activity of NF-κB and AP-1 and the expressions of downstream targets, IL-6 and cyclooxygenase 2 (COX-2) in CRC cells119.